Streetbeat News

Equity Actions

LUCD

Lucid's Chairman and CEO announced the company has strengthened its balance sheet by closing approximately $30M in preferred stock financing with long-term investors. This move extends Lucid's financial runway past key milestones. Additionally, the CEO highlighted the ongoing success of EsoGuard's commercial execution, which is driving towards expanded coverage both in the private and public sectors, as well as through direct contracting.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 12:08 pm

VVX

V2X, Inc. has announced the appointment of Jeremy Wensinger as its new President and CEO. This strategic leadership change aims to steer the company towards future growth and operational excellence.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 12:03 pm

QLYS

Qualys (NASDAQ:QLYS) received indifferent ratings from 4 analysts, with a consensus 12-month price target of $169.25, marking a 3.29% decline from the previous target. The company's financial performance shows strong revenue growth, net margin, ROE, and ROA, with minimal debt reliance.

Portfolio Pulse from Benzinga Insights

May 13, 2024 | 12:01 pm

AGS

Five analysts have recently updated their ratings on PlayAGS (NYSE:AGS), showing a mix of bullish and indifferent stances with an updated average 12-month price target of $13.5, up from $12.33. The company has seen positive revenue growth and operates in the gaming industry, supplying electronic gaming machines and other gaming products. Despite revenue growth, PlayAGS faces challenges with profitability, asset utilization, and debt management.

Portfolio Pulse from Benzinga Insights

May 13, 2024 | 12:00 pm

JAN

JanOne acquires blockchain FinTech firm ALT 5 Sigma, issuing 1,799,100 common and 34,207 Series B preferred shares, making ALT 5 Sigma a wholly owned subsidiary.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 11:48 am

INKT

MiNK Therapeutics announced a private placement financing deal to raise $5.8 million, specifically aimed at accelerating the clinical trials of MiNK-215.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 11:31 am

AUTL

Autolus Therapeutics has postponed its Q1 2024 earnings release and conference call originally scheduled for May 14, 2024. The company plans to file its Q1 2024 10-Q by May 20, 2024, at the latest.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 11:27 am

BYD

Boyd Gaming announces an additional $500M share repurchase authorization, bringing its total repurchase authority to $721M as of March 31, 2024. Also, a quarterly cash dividend of $0.17 per share is declared, payable on July 15, 2024, to shareholders of record as of June 15, 2024.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 11:16 am

KVUE

Kenvue shares are trading lower following the announcement of a secondary offering by selling shareholders.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 11:15 am

LPTX

Leap Therapeutics announced that the net proceeds from its April 2024 financing of $37.2M, along with its existing cash, cash equivalents, and marketable securities totaling $54.9M, are expected to extend its cash runway into the second quarter of 2026.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 11:11 am